This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Nintedanib in PF-ILD

  • Research type

    Research Study

  • Full title

    An open-label extension trial of the long-term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

  • IRAS ID

    252018

  • Contact name

    Simon Daniels

  • Contact email

    simon.daniels@boehringer-ingelheim.com

  • Sponsor organisation

    Boehringer Ingelheim

  • Eudract number

    2018-000525-32

  • Duration of Study in the UK

    3 years, 3 months, 15 days

  • Research summary

    A phase III extension study investigating long term treatment with nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have completed (and did not prematurely discontinue trial medication in) the phase III parent trial, 1199.247 (INBUILD). We aim to explore the long-term safety of nintedanib in patients with progressive scarring of the lungs.

  • REC name

    East Midlands - Leicester Central Research Ethics Committee

  • REC reference

    18/EM/0365

  • Date of REC Opinion

    14 Jan 2019

  • REC opinion

    Further Information Favourable Opinion